|
COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models. |
|
|
No Relationships to Disclose |
|
|
Employment - Cotinga Pharmaceuticals |
Stock and Other Ownership Interests - Cotinga Pharmaceuticals |
Research Funding - Cotinga Pharmaceuticals |
Travel, Accommodations, Expenses - Cotinga Pharmaceuticals |
Other Relationship - Cotinga Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Alnylam; Cotinga Pharmaceuticals; Leap Therapeutics (I) |
Stock and Other Ownership Interests - Alnylam; Leap Therapeutics (I) |
|
|
Employment - Cotinga Pharmaceuticals; Synlogic |
Leadership - Cotinga Pharmaceuticals; Synlogic |
Stock and Other Ownership Interests - Cotinga Pharmaceuticals; Synlogic |
Consulting or Advisory Role - Cotinga Pharmaceuticals |
Research Funding - Cotinga Pharmaceuticals; Synlogic |
Travel, Accommodations, Expenses - Cotinga Pharmaceuticals; Synlogic |